Patent US4585742A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4585742A Expired / Lapsed US ⏱️ 0.0 years remaining

Monoclonal antibody with specificity to human small cell carcinoma and use thereof

Assignee: Dana Farber Cancer Institute Inc
•
Filing: 1983-12-14
•
Granted: 1986-04-29
•
Expires: 2003-12-14
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Monoclonal antibody reactive with SCC cells and unreactive with human neuroblastoma cells, human squamous cell carcinoma cells, and human large-cell undifferentiated lung carcinoma cells.

Inventors

  • 👤 Samuel D. Bernal

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-02 18:03
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; C07K16/3023; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S436/00; Y10S436/811; Y10S436/813; Y10S436/821; Y10S530/00; Y10S530/863; Y10S530/864

Claims Analysis

Total Claims: 23
Claim 1
Independent Claim 77 words
A monoclonal antibody which strongly binds to small cell carcinoma cells compared to the binding of said monoclonal antibody to human neuroblastoma cells, human squamus cell carcinoma cells, and human large-cell undifferentiated lung carcinoma cells, in a radioimmunoassay in which said cells are incubated with said monoclonal antibody and a radiolabeled second antibody capable of binding to said monoclonal antibody, said antibody recognizing an approximately 50,000 dalton antigenic determinant on the surface of small cell carcinoma cells.
Claim 2
Dependent Claim 77 words
A monoclonal antibody which strongly binds to small cell carcinoma cells compared to the binding of said monoclonal antibody to human neuroblastoma cells, human squamus cell carcinoma cells, and human large-cell undifferentiated lung carcinoma cells, in a radioimmunoassay in which said cells are incubated with said monoclonal antibody and a radiolabeled second antibody capable of binding to said monoclonal antibody, said antibody recognizing an approximately 50,000 dalton antigenic determinant on the surface of small cell carcinoma cells.
Claim 3
Dependent Claim 15 words
The antibody of claim 1, wherein said antibody is of the IgM or IgG2 isotype.
Claim 4
Dependent Claim 23 words
The antibody of claim 1, wherein said antibody recognizes an approximately 25,000 dalton antigenic determinant on the surface of small cell carcinoma cells.
Claim 5
Dependent Claim 14 words
The antibody of claim 1, wherein said antibody is coupled to a cytotoxic agent.
Claim 6
Dependent Claim 14 words
The antibody of claim 1, wherein said antibody is labeled with a detectable label.
Claim 7
Dependent Claim 10 words
The antibody of claim 5, wherein said antibody is radiolabeled.
Claim 8
Dependent Claim 11 words
The antibody of claim 5, wherein said antibody is fluorescently labeled.
Claim 9
Dependent Claim 23 words
The antibody of claim 1, wherein said antibody is capable, in the presence of complement, of lysing small cell carcinoma cells in vitro.
Claim 10
Dependent Claim 13 words
The monoclonal antibody produced by the hybridoma cell given ATCC Accession No. HB8462.
Claim 11
Dependent Claim 13 words
The monoclonal antibody produced by the hybridoma cell given ATCC Accession No. HB8462.
Claim 12
Dependent Claim 27 words
A hybridoma cell capable of producing a monoclonal antibody having the immunological identifying characteristics of the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB8462.
Claim 13
Dependent Claim 27 words
A hybridoma cell capable of producing a monoclonal antibody having the immunological identifying characteristics of the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB8462.
Claim 14
Dependent Claim 8 words
The hybridoma cell given ATTC Accession No. HB8462.
Claim 15
Dependent Claim 8 words
The hybridoma cell given ATTC Accession No. HB8462.
Claim 16
Independent Claim 72 words
A method of detecting the presence of small cell carcinoma cells in a human patient comprising incubating a cell-containing clinical sample from said patient with a monoclonal antibody having the immunological identifying characteristics of the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB 8462 under conditions sufficient to permit formation of immune complexes and detecting said immune complexes as an indication of the presence of small cell carcinoma cells.
Claim 17
Independent Claim 72 words
A method of detecting the presence of small cell carcinoma cells in a human patient comprising incubating a cell-containing clinical sample from said patient with a monoclonal antibody having the immunological identifying characteristics of the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB 8462 under conditions sufficient to permit formation of immune complexes and detecting said immune complexes as an indication of the presence of small cell carcinoma cells.
Claim 18
Independent Claim 48 words
A method of lysing small cell carcinoma cells in a clinical sample comprising incubating said sample with a monoclonal antibody having the immunological identifying characteristic of the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB8462 in the presence of complement under conditions which permit lysis.
Claim 19
Independent Claim 48 words
A method of lysing small cell carcinoma cells in a clinical sample comprising incubating said sample with a monoclonal antibody having the immunological identifying characteristic of the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB8462 in the presence of complement under conditions which permit lysis.
Claim 20
Independent Claim 58 words
A method of lysing small cell carcinoma cells in a clinical sample from a patient comprising incubating said sample with an immunotoxin consisting of (1) a monoclonal antibody having the immunological identifying characteristics of the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB8462 and (2) covalently bound thereto a cytotoxin; under conditions with permit lysis.
Claim 21
Independent Claim 58 words
A method of lysing small cell carcinoma cells in a clinical sample from a patient comprising incubating said sample with an immunotoxin consisting of (1) a monoclonal antibody having the immunological identifying characteristics of the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB8462 and (2) covalently bound thereto a cytotoxin; under conditions with permit lysis.
Claim 22
Dependent Claim 79 words
A monoclonal antibody which strongly binds to small cell carcinoma cells compared to the binding of said monoclonal antibody to human neuroblastoma cells, human squamus cell carcinoma cells, and human large-cell undifferentiated lung carcinoma cells, in an indirect immunofluorescence assay in which said cells are incubated with said monoclonal antibody and a fluorescein-labeled second antibody capable of binding to said monoclonal antibody, said antibody recognizing an approximately 50,000 dalton antigenic determinant on the surface of small cell carcinoma cells.
Claim 23
Dependent Claim 79 words
A monoclonal antibody which strongly binds to small cell carcinoma cells compared to the binding of said monoclonal antibody to human neuroblastoma cells, human squamus cell carcinoma cells, and human large-cell undifferentiated lung carcinoma cells, in an indirect immunofluorescence assay in which said cells are incubated with said monoclonal antibody and a fluorescein-labeled second antibody capable of binding to said monoclonal antibody, said antibody recognizing an approximately 50,000 dalton antigenic determinant on the surface of small cell carcinoma cells.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1989-04-28 1989-10-28 1990-04-29 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1993-04-28 1993-10-28 1994-04-29 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1997-04-28 1997-10-28 1998-04-29 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag